SCHEDULE: Point72 Discloses 2.6% Stake in Amylyx Pharmaceuticals
Beneficial Ownership Report
Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen have jointly reported a 2.6% beneficial ownership stake in Amylyx Pharmaceuticals, Inc.
Summary
- Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen collectively hold 2,801,636 shares of Amylyx Pharmaceuticals, Inc. common stock.
- This beneficial ownership represents 2.6% of the class of securities.
- The reporting persons share both voting and dispositive power over all 2,801,636 shares.
- The filing is an Amendment No. 1 to a Schedule 13G, indicating a change or update to a previously reported ownership position.
- The event date requiring this filing was September 30, 2025, with the filing signed on November 14, 2025.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of beneficial ownership and does not contain information that is inherently positive or negative for the issuer. A 2.6% passive stake indicates institutional interest but no immediate strategic implications.
Future Outlook
This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance from Amylyx Pharmaceuticals, Inc. or the reporting persons regarding the issuer's future performance or strategic direction.
Industry Context
This filing indicates an institutional investment firm, Point72 Asset Management, has taken a passive stake in Amylyx Pharmaceuticals, a company operating in the biotechnology and pharmaceutical sector. Such disclosures are common and reflect ongoing portfolio adjustments by large investment funds within the industry.
Stakeholder Impact
- Shareholders: The disclosure of a 2.6% stake by a prominent investment firm like Point72 may signal institutional confidence or interest in Amylyx Pharmaceuticals, potentially influencing investor sentiment.
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of event which requires the filing of this statement, indicating the beneficial ownership position. |
| 11/14/2025 | Date the Schedule 13G Amendment No. 1 was signed and filed by the reporting persons. |
Keywords
Amylyx Pharmaceuticals, Point72 Asset Management, Steven A. Cohen, Beneficial Ownership, Schedule 13G, Common Stock, Biotechnology, Pharmaceuticals, Institutional Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.